Celon Pharma SA (CLN) AI Stock Analysis

Celon Pharma SA

(Warsaw:CLN)

Select Model

Rating:42Neutral

Price Target:PLN 21.00▲(19.45% Upside)

Action:initiatedcoverage

Date:09/16/25

The stock score is most heavily impacted by persistent and worsening financial weakness—sustained losses and negative cash flow pose immediate risks despite conservative debt levels. Secondary factors reinforce the weak outlook: a high P/E ratio and near-zero yield underscore overvaluation concerns with virtually no technical support or reversal signals.

Positive Factors

Strong Gross Profit MarginA strong gross profit margin indicates effective cost management and pricing power, which can support long-term profitability as the company scales.

Negative Factors

Negative Revenue GrowthNegative revenue growth suggests challenges in maintaining sales momentum, which can hinder long-term business sustainability and market competitiveness.

Celon Pharma SA (CLN) vs. SPDR S&P 500 ETF (SPY)

Market Cap: PLN 921.89M
Dividend Yield: ―
Average Volume (3M): 21.04K
Price to Earnings (P/E): 8.4
Beta (1Y): 0.56
Revenue Growth: ―
EPS Growth: ―
Country: PL
Employees: 560
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Celon Pharma SA Business Overview & Revenue Model

Company Description

Celon Pharma S.A. operates as a fully-integrated pharmaceutical firm, undertaking the investigation, development, production, and distribution of diverse medicinal formulations. Its business model is structured around two principal areas: generic dru...

How the Company Makes Money

Celon Pharma generates revenue primarily through the development and sale of its pharmaceutical products, as well as through strategic partnerships and collaborations with other biotechnology and pharmaceutical companies. Key revenue streams include...

Celon Pharma SA Financial Statement Overview

Summary

Celon Pharma SA exhibits severe profitability and cash flow challenges. Revenues declined, margins are negative, and both net income and operating cash flow remain in deficit. While the company's low leverage and solid gross margin are positives, sustained losses and cash burn reflect acute financial distress with no immediate sign of improvement.

Income Statement

28Negative

Balance Sheet

61Positive

Cash Flow

19Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	216.85M	209.80M	176.62M	213.92M	161.91M	196.09M
Gross Profit	14.66M	-39.48M	113.45M	147.10M	95.45M	134.37M
EBITDA	8.26M	-10.48M	14.96M	32.71M	9.32M	27.81M
Net Income	110.77M	-79.36M	-34.45M	-28.12M	-39.28M	-11.61M
Balance Sheet
Total Assets	733.42M	457.46M	543.79M	569.31M	608.93M	707.14M
Cash, Cash Equivalents and Short-Term Investments	34.53M	19.91M	56.52M	114.54M	164.62M	227.55M
Total Debt	128.44M	18.94M	16.93M	25.59M	26.82M	14.92M
Total Liabilities	234.86M	74.47M	98.59M	123.75M	129.29M	153.14M
Stockholders Equity	498.57M	363.25M	445.21M	445.56M	479.65M	554.00M
Cash Flow
Free Cash Flow	-56.63M	-30.57M	-34.13M	-41.13M	-38.61M	2.60M
Operating Cash Flow	27.29M	23.86M	-11.34M	-8.31M	-4.70M	43.95M
Investing Cash Flow	-82.72M	-21.64M	-7.49M	-21.64M	-31.47M	-121.05M
Financing Cash Flow	67.07M	-9.76M	13.32M	-20.59M	-28.72M	180.91M

Celon Pharma SA Technical Analysis

Technical Analysis SentimentNegative

Last Price17.58

Price Trends

50DMA20.01Negative

100DMA20.23Negative

200DMA20.78Negative

Market Momentum

MACD-0.63Positive

RSI35.37Neutral

STOCH21.60Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:CLN, the sentiment is Negative. The current price of 17.58 is below the 20-day moving average (MA) of 18.71, below the 50-day MA of 20.01, and below the 200-day MA of 20.78, indicating a bearish trend. The MACD of -0.63 indicates Positive momentum. The RSI at 35.37 is Neutral, neither overbought nor oversold. The STOCH value of 21.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PL:CLN.

Celon Pharma SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

PL:CLN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PL:CLN	42Neutral	PLN 921.89M	8.37	24.89%	―	―	―
PL:MAB	41Neutral	PLN 127.68M	-2.26	-124.37%	―	56.67%	12.68%
PL:SLV	40Underperform	PLN 308.37M	-132.23	-0.66%	―	-8.26%	-548.22%
PL:RVU	37Underperform	PLN 392.58M	-5.39	-139.66%	―	-11.57%	43.60%
PL:CTX	34Underperform	PLN 337.20M	-6.57	-132.32%	―	-81.93%	-3.31%

* Healthcare Sector Average

Performance Comparison

PL:CLN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
PL:CLN	Celon Pharma SA	17.58	-4.12	-18.99%
PL:RVU	Ryvu Therapeutics SA	16.22	-8.58	-34.60%
PL:CTX	Captor Therapeutics SA	51.00	2.10	4.29%
PL:MOC	OncoArendi Therapeutics SA	5.68	-0.55	-8.83%
PL:SLV	Selvita SA	16.00	-23.70	-59.70%
PL:MAB	Mabion SA	7.90	-0.22	-2.71%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 16, 2025

Celon Pharma SA AI Stock Analysis